Shahram Arsang-Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shahram Arsang-Jang has a total of 324 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Taheri
Institute of Human Genetics, Jena University Hospital, Jena, Germany; Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
47 shared publications - Soudeh Ghafouri-Fard
Shahid Beheshti University of Medical Sciences, Tehran, Iran
34 shared publications Mehrdokht Mazdeh
Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
14 shared publicationsMir Davood Omrani
Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
13 shared publicationsArezou Sayad
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
9 shared publications- Mir Davood Omrani
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
9 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72315
Mitochondrial Genomic Alterations in Pediatric Acute Lymphoblastic Leukemia: Implications for Methotrexate‐Induced Neurotoxicity and Ethnic Disparities
Methotrexate (MTX)‐induced neurotoxicity is a serious complication in pediatric acute lymphoblastic leukemia (ALL), with observed ethnic disparities in risk. To investigate the role of mitochondrial DNA (mtDNA) variation, we performed whole mtDNA sequencing in 94 children with ALL, including 62 Hispanic patients. We identified 1294 mtDNA variants, including 12.4% novel variants, with MT‐ND5 and the D‐loop representing major variant hotspots. Gene‐based analyses identified significant associations of MT‐ND6 and MT‐ND2 with MTX neurotoxicity after multiple testing correction. Heteroplasmy was more frequent in affected patients, and predictive models incorporating mtDNA variants improved discrimination (AUC = 0.78) compared with clinical factors alone. These findings suggest that mtDNA variation, particularly involving Complex I genes, may contribute to MTX neurotoxicity and support its potential utility for risk stratification, while requiring validation in independent cohorts.
- 23 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72315
Open AccessMitochondrial Genomic Alterations in Pediatric Acute Lymphoblastic Leukemia: Implications for Methotrexate‐Induced Neurotoxicity and Ethnic Disparities
Methotrexate (MTX)‐induced neurotoxicity is a serious complication in pediatric acute lymphoblastic leukemia (ALL), with observed ethnic disparities in risk. To investigate the role of mitochondrial DNA (mtDNA) variation, we performed whole mtDNA sequencing in 94 children with ALL, including 62 Hispanic patients. We identified 1294 mtDNA variants, including 12.4% novel variants, with MT‐ND5 and the D‐loop representing major variant hotspots. Gene‐based analyses identified significant associations of MT‐ND6 and MT‐ND2 with MTX neurotoxicity after multiple testing correction. Heteroplasmy was more frequent in affected patients, and predictive models incorporating mtDNA variants improved discrimination (AUC = 0.78) compared with clinical factors alone. These findings suggest that mtDNA variation, particularly involving Complex I genes, may contribute to MTX neurotoxicity and support its potential utility for risk stratification, while requiring validation in independent cohorts.
- Open Access
- 1 December 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (149) , 567-573
The Correlation between HSP27 Protein Levels and Gene Expression with Symptoms Severity in COVID-19 Patients
Background and Objective: Heat shock proteins (HSPs) have garnered significant interest as a potential host factor in COVID-19. By exerting control over HSP levels, the invading virus can effectively manipulate the destiny of host cells, capitalizing on their essential roles in cellular pathways and viral life cycles. Within this investigation, we present ...
- 1 December 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (149) , 567-573
Open AccessThe Correlation between HSP27 Protein Levels and Gene Expression with Symptoms Severity in COVID-19 Patients
Background and Objective: Heat shock proteins (HSPs) have garnered significant interest as a potential host factor in COVID-19. By exerting control over HSP levels, the invading virus can effectively manipulate the destiny of host cells, capitalizing on their essential roles in cellular pathways and viral life cycles. Within this investigation, we present ...
- Open Access
- 29 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6295
Multimodal Imaging of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer—A State-of-the-Art Review
Background: This review focuses on multimodality imaging of cardiotoxicity in cancer patients, with the aim of evaluating the effectiveness of different techniques in detecting and monitoring cardiac changes associated with cancer therapy. Methods: Eight studies were included in the review, covering various imaging modalities such as cardiac magnetic resonance imaging, echocardiography, and multigated acquisition scanning. Results: Cardiac magnetic resonance imaging emerged as the most definitive modality, offering real-time detection, comprehensive assessment of cardiac function, the ability to detect early myocardial changes, and superior detection of cardiotoxicity when compared to the other imaging modalities. The studies also emphasize the importance of parameters such as left ventricular ejection fraction and global longitudinal strain in assessing cardiac function and predicting cardiotoxicity. Conclusion: Due to the common use of HER2 agents and anthracyclines within the breast cancer population, the LVEF as a critical prognostic measurement for assessing heart health and estimating the severity of left-sided cardiac malfunction is a commonly used endpoint. CTRCD rates differed between imaging modalities, with cardiac MRI the most sensitive. The use of multimodal cardiac imaging remains a nuanced area, influenced by local availability, the clinical question at hand, body habits, and medical comorbidities. All of the imaging modalities listed have a role to play in current care; however, focus should be given to increasing the provision of cardiac MRI for breast cancer patients in the future to optimize the detection of CTRCD and patient outcomes thereafter.
- 29 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6295
Open AccessMultimodal Imaging of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer—A State-of-the-Art Review
Background: This review focuses on multimodality imaging of cardiotoxicity in cancer patients, with the aim of evaluating the effectiveness of different techniques in detecting and monitoring cardiac changes associated with cancer therapy. Methods: Eight studies were included in the review, covering various imaging modalities such as cardiac magnetic resonance imaging, echocardiography, and multigated acquisition scanning. Results: Cardiac magnetic resonance imaging emerged as the most definitive modality, offering real-time detection, comprehensive assessment of cardiac function, the ability to detect early myocardial changes, and superior detection of cardiotoxicity when compared to the other imaging modalities. The studies also emphasize the importance of parameters such as left ventricular ejection fraction and global longitudinal strain in assessing cardiac function and predicting cardiotoxicity. Conclusion: Due to the common use of HER2 agents and anthracyclines within the breast cancer population, the LVEF as a critical prognostic measurement for assessing heart health and estimating the severity of left-sided cardiac malfunction is a commonly used endpoint. CTRCD rates differed between imaging modalities, with cardiac MRI the most sensitive. The use of multimodal cardiac imaging remains a nuanced area, influenced by local availability, the clinical question at hand, body habits, and medical comorbidities. All of the imaging modalities listed have a role to play in current care; however, focus should be given to increasing the provision of cardiac MRI for breast cancer patients in the future to optimize the detection of CTRCD and patient outcomes thereafter.
- Open Access
- 22 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (14) , 4835
Predictors of Conduction Disturbances Requiring New Permanent Pacemaker Implantation following Transcatheter Aortic Valve Implantation Using the Evolut Series
(1) Background: Conduction disturbance requiring a new permanent pacemaker (PPM) after transcatheter aortic valve implantation (TAVI) has traditionally been a common complication. New implantation techniques with self-expanding platforms have reportedly reduced the incidence of PPM. We sought to investigate the predictors of PPM at 30 days after TAVI using Evolut R/PRO/PRO+; (2) Methods: Consecutive patients who underwent TAVI with the Evolut platform between October 2019 and August 2022 at University Hospital Galway, Ireland, were included. Patients who had a prior PPM (n = 10), valve-in-valve procedures (n = 8) or received >1 valve during the index procedure (n = 3) were excluded. Baseline clinical, electrocardiographic (ECG), echocardiographic and multislice computed tomography (MSCT) parameters were analyzed. Pre-TAVI MSCT analysis included membranous septum (MS) length, a semi-quantitative calcification analysis of the aortic valve leaflets, left ventricular outflow tract, and mitral annulus. Furthermore, the implantation depth (ID) was measured from the final aortography. Multivariate binary logistic analysis and receiver operating characteristic (ROC) curve analysis were used to identify independent predictors and the optimal MS and ID cutoff values to predict new PPM requirements, respectively; (3) Results: A total of 129 TAVI patients were included (age = 81.3 ± 5.3 years; 36% female; median EuroSCORE II 3.2 [2.0, 5.4]). Fifteen patients (11.6%) required PPM after 30 days. The patients requiring new PPM at 30 days were more likely to have a lower European System for Cardiac Operative Risk Evaluation II, increased prevalence of right bundle branch block (RBBB) at baseline ECG, have a higher mitral annular calcification severity and have a shorter MS on preprocedural MSCT analysis, and have a ID, as shown on the final aortogram. From the multivariate analysis, pre-TAVI RBBB, MS length, and ID were shown to be predictors of new PPM. An MS length of 3.99 mm (area under the curve (AUC) = 0.79, (95% confidence interval (CI): (0.68, 0.90)) were found to be the optimal cut-offs for predicting new PPM requirements; (4) Conclusions: Membranous septum length and implantation depth were found to be independent predictors of new PPM post-TAVI with the Evolut platform. Patient-specific implantation depth could be used to mitigate the requirement for new PPM.
- 22 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (14) , 4835
Open AccessPredictors of Conduction Disturbances Requiring New Permanent Pacemaker Implantation following Transcatheter Aortic Valve Implantation Using the Evolut Series
(1) Background: Conduction disturbance requiring a new permanent pacemaker (PPM) after transcatheter aortic valve implantation (TAVI) has traditionally been a common complication. New implantation techniques with self-expanding platforms have reportedly reduced the incidence of PPM. We sought to investigate the predictors of PPM at 30 days after TAVI using Evolut R/PRO/PRO+; (2) Methods: Consecutive patients who underwent TAVI with the Evolut platform between October 2019 and August 2022 at University Hospital Galway, Ireland, were included. Patients who had a prior PPM (n = 10), valve-in-valve procedures (n = 8) or received >1 valve during the index procedure (n = 3) were excluded. Baseline clinical, electrocardiographic (ECG), echocardiographic and multislice computed tomography (MSCT) parameters were analyzed. Pre-TAVI MSCT analysis included membranous septum (MS) length, a semi-quantitative calcification analysis of the aortic valve leaflets, left ventricular outflow tract, and mitral annulus. Furthermore, the implantation depth (ID) was measured from the final aortography. Multivariate binary logistic analysis and receiver operating characteristic (ROC) curve analysis were used to identify independent predictors and the optimal MS and ID cutoff values to predict new PPM requirements, respectively; (3) Results: A total of 129 TAVI patients were included (age = 81.3 ± 5.3 years; 36% female; median EuroSCORE II 3.2 [2.0, 5.4]). Fifteen patients (11.6%) required PPM after 30 days. The patients requiring new PPM at 30 days were more likely to have a lower European System for Cardiac Operative Risk Evaluation II, increased prevalence of right bundle branch block (RBBB) at baseline ECG, have a higher mitral annular calcification severity and have a shorter MS on preprocedural MSCT analysis, and have a ID, as shown on the final aortogram. From the multivariate analysis, pre-TAVI RBBB, MS length, and ID were shown to be predictors of new PPM. An MS length of 3.99 mm (area under the curve (AUC) = 0.79, (95% confidence interval (CI): (0.68, 0.90)) were found to be the optimal cut-offs for predicting new PPM requirements; (4) Conclusions: Membranous septum length and implantation depth were found to be independent predictors of new PPM post-TAVI with the Evolut platform. Patient-specific implantation depth could be used to mitigate the requirement for new PPM.
- Open Access
- 1 June 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (146) , 210-220
Assessment of Machine Learning Approaches to Predict in-Hospital Mortality in Patients Underwent Prosthetic Heart Valve Replacement Surgery
Background and Objective: Machine learning and artificial intelligence are useful tools to analyze data with multiple variables. It has been shown that the prediction models obtained by Machine learning have better performance than the conventional statistical methods. This study was aimed to assess the risk factors and determine the best machine ...
- 1 June 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (146) , 210-220
Open AccessAssessment of Machine Learning Approaches to Predict in-Hospital Mortality in Patients Underwent Prosthetic Heart Valve Replacement Surgery
Background and Objective: Machine learning and artificial intelligence are useful tools to analyze data with multiple variables. It has been shown that the prediction models obtained by Machine learning have better performance than the conventional statistical methods. This study was aimed to assess the risk factors and determine the best machine ...
- Open Access
- 4 May 2023
- Published by Springer Nature in Research Square
Bayesian spatio-temporal modeling of hyperlipidemia risk in Iran; A repeated cross-sectional analysis
Background:There is little information about the use of hierarchical Bayesian approaches to accurately investigate the spatial distribution of relative risk of hyperlipidemia in Iran. In this research, we used hierarchical Bayesian models and examined the spatial distribution of relative risk of hyperlipidemia in separate provinces throughout Iran. Methods:in this study, all individuals with hyperlipidemia in all provinces of Iran in 2019. The main variables of the study included average age, gender, and number of cases of hyperlipidemia in each province. The population of each province was obtained from the Iranian Statistics Center, and was used to compute the disease prevalence, and the expected number of cases. Besag-York-Mollié (BYM) and Besag-York-Mollié 2 (BYM2) models to analyze data and Hamiltonian Monte Carlo method was also applied for parameter estimation. Results:The relative risk of hyperlipidemia was greater than 1 in 16% (95% CI: (0.304, 0.879)) of Iranian provinces (posterior probability > 0.8). Therefore, those aged >50 years old in Fars, Isfahan, Khuzestan, Razavi Khorasan and Tehran provinces were increasingly at risk of hyperlipidemia. The study found that women aged >70 years had the lowest average incidence of hyperlipidemia (RR=-0.86; 95% CI: (-1.13, -.0463)), while men aged 65-69 had the highest average incidence (RR=1.41; 95% CI: (-0.674, -0.129)). Conclusions: Our results show various relative risks of hyperlipidemia in different regions of the country, with some provinces at a higher risk. Moreover, the finding that women aged 70 years and above have the lowest average incidence of hyperlipidemia highlights the importance of early detection and management of the condition in younger age groups. Healthcare providers should focus on preventive measures, such as regular health screenings and lifestyle modifications, to reduce the risk of hyperlipidemia in high-risk populations.
- 4 May 2023
- Published by Springer Nature in Research Square
Open AccessBayesian spatio-temporal modeling of hyperlipidemia risk in Iran; A repeated cross-sectional analysis
Background:There is little information about the use of hierarchical Bayesian approaches to accurately investigate the spatial distribution of relative risk of hyperlipidemia in Iran. In this research, we used hierarchical Bayesian models and examined the spatial distribution of relative risk of hyperlipidemia in separate provinces throughout Iran. Methods:in this study, all individuals with hyperlipidemia in all provinces of Iran in 2019. The main variables of the study included average age, gender, and number of cases of hyperlipidemia in each province. The population of each province was obtained from the Iranian Statistics Center, and was used to compute the disease prevalence, and the expected number of cases. Besag-York-Mollié (BYM) and Besag-York-Mollié 2 (BYM2) models to analyze data and Hamiltonian Monte Carlo method was also applied for parameter estimation. Results:The relative risk of hyperlipidemia was greater than 1 in 16% (95% CI: (0.304, 0.879)) of Iranian provinces (posterior probability > 0.8). Therefore, those aged >50 years old in Fars, Isfahan, Khuzestan, Razavi Khorasan and Tehran provinces were increasingly at risk of hyperlipidemia. The study found that women aged >70 years had the lowest average incidence of hyperlipidemia (RR=-0.86; 95% CI: (-1.13, -.0463)), while men aged 65-69 had the highest average incidence (RR=1.41; 95% CI: (-0.674, -0.129)). Conclusions: Our results show various relative risks of hyperlipidemia in different regions of the country, with some provinces at a higher risk. Moreover, the finding that women aged 70 years and above have the lowest average incidence of hyperlipidemia highlights the importance of early detection and management of the condition in younger age groups. Healthcare providers should focus on preventive measures, such as regular health screenings and lifestyle modifications, to reduce the risk of hyperlipidemia in high-risk populations.
- Open Access
- 20 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2398
One-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% of candidates for aortic valve replacement (AVR). Despite increasingly utilised transcatheter aortic valve implantation (TAVI) in aortic stenosis (AS) patients, its use among patients with severe bicuspid AS is limited as BAV is a heterogeneous disease associated with multiple and complex anatomical challenges. Aim: To investigate the one-year outcomes of TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., Vapi, India) in patients with severe bicuspid AS. Methods and results: We collected data from consecutive patients with bicuspid AS who underwent TAVI with the Myval THV and had at least one-year follow-up. Baseline characteristics, procedural, and 30-day echocardiographic and clinical outcomes were collected. Sixty-two patients were included in the study. The median age was 72 [66.3, 77.0] years, 45 (72.6%) were males, and the mean STS PROM score was 3.2 ± 2.2%. All TAVI procedures were performed via the transfemoral route. The median follow-up duration was 13.5 [12.2, 18.3] months; all-cause mortality was reported in 7 (11.3%) patients and cardiovascular hospitalisation in 6 (10.6%) patients. All-stroke was reported in 2 (3.2%), permanent pacemaker implantation 5 (8.3%), and myocardial infarction 1 (1.6%) patients. The echocardiographic assessment revealed a mean pressure gradient of 10 [8, 16.5] mmHg, effective orifice area 1.7 [1.4, 1.9] cm2, moderate AR in 1 (2%), mild AR in 14 (27%), and none/trace AR in 37 (71%). In total, 1 patient was diagnosed with valve thrombosis (2.1%), Stage II (moderate) haemodynamic deterioration was seen in 3 (6.4%), and stage III (severe) haemodynamic deterioration in 1 (2.1%) patient. Conclusions: TAVI with the Myval THV in selected BAV anatomy is associated with favourable one-year hemodynamic and clinical outcomes.
- 20 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2398
Open AccessOne-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% of candidates for aortic valve replacement (AVR). Despite increasingly utilised transcatheter aortic valve implantation (TAVI) in aortic stenosis (AS) patients, its use among patients with severe bicuspid AS is limited as BAV is a heterogeneous disease associated with multiple and complex anatomical challenges. Aim: To investigate the one-year outcomes of TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., Vapi, India) in patients with severe bicuspid AS. Methods and results: We collected data from consecutive patients with bicuspid AS who underwent TAVI with the Myval THV and had at least one-year follow-up. Baseline characteristics, procedural, and 30-day echocardiographic and clinical outcomes were collected. Sixty-two patients were included in the study. The median age was 72 [66.3, 77.0] years, 45 (72.6%) were males, and the mean STS PROM score was 3.2 ± 2.2%. All TAVI procedures were performed via the transfemoral route. The median follow-up duration was 13.5 [12.2, 18.3] months; all-cause mortality was reported in 7 (11.3%) patients and cardiovascular hospitalisation in 6 (10.6%) patients. All-stroke was reported in 2 (3.2%), permanent pacemaker implantation 5 (8.3%), and myocardial infarction 1 (1.6%) patients. The echocardiographic assessment revealed a mean pressure gradient of 10 [8, 16.5] mmHg, effective orifice area 1.7 [1.4, 1.9] cm2, moderate AR in 1 (2%), mild AR in 14 (27%), and none/trace AR in 37 (71%). In total, 1 patient was diagnosed with valve thrombosis (2.1%), Stage II (moderate) haemodynamic deterioration was seen in 3 (6.4%), and stage III (severe) haemodynamic deterioration in 1 (2.1%) patient. Conclusions: TAVI with the Myval THV in selected BAV anatomy is associated with favourable one-year hemodynamic and clinical outcomes.
- Open Access
- 6 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1278
Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer
Background: This paper looks to validate the risk score from the Heart Failure Association of the European Society of Cardiology and the International Cardio-Oncology Society (HFA-ICOS) for predicting potential cardiotoxicity from anticancer therapy for patients positive for human epidermal growth factor receptor 2. Methods: A total of 507 patients with at least five years since index diagnosis of breast cancer were retrospectively divided according to the HFA-ICOS risk proforma. According to level of risk, these groups were assessed for rates of cardiotoxicity via mixed-effect Bayesian logistic regression model. Results: A follow-up of five years observed cardiotoxicity of 3.3% (n = 3) in the low-risk, 3.3% (n = 10) in the medium-risk, 4.4% (n = 6) in the high-risk, and 38% (n = 6) in the very-high-risk groups respectively. For cardiac events related to treatment, the risk was significantly higher for the very-high-risk category of HFA-ICOS compared to other categories (Beta = 3.1, 95% CrI: 1.5, 4.8). For overall cardiotoxicity related to treatment, the area under the curve was 0.643 (CI 95%: 0.51, 0.76), with 26.1% (95% CI: 8%, 44%) sensitivity and 97.9% (95% CI: 96%, 99%) specificity. Conclusions: The HFA-ICOS risk score has moderate power in predicting cancer therapy–related cardiotoxicity in HER2-positive breast cancer patients.
- 6 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1278
Open AccessHeart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer
Background: This paper looks to validate the risk score from the Heart Failure Association of the European Society of Cardiology and the International Cardio-Oncology Society (HFA-ICOS) for predicting potential cardiotoxicity from anticancer therapy for patients positive for human epidermal growth factor receptor 2. Methods: A total of 507 patients with at least five years since index diagnosis of breast cancer were retrospectively divided according to the HFA-ICOS risk proforma. According to level of risk, these groups were assessed for rates of cardiotoxicity via mixed-effect Bayesian logistic regression model. Results: A follow-up of five years observed cardiotoxicity of 3.3% (n = 3) in the low-risk, 3.3% (n = 10) in the medium-risk, 4.4% (n = 6) in the high-risk, and 38% (n = 6) in the very-high-risk groups respectively. For cardiac events related to treatment, the risk was significantly higher for the very-high-risk category of HFA-ICOS compared to other categories (Beta = 3.1, 95% CrI: 1.5, 4.8). For overall cardiotoxicity related to treatment, the area under the curve was 0.643 (CI 95%: 0.51, 0.76), with 26.1% (95% CI: 8%, 44%) sensitivity and 97.9% (95% CI: 96%, 99%) specificity. Conclusions: The HFA-ICOS risk score has moderate power in predicting cancer therapy–related cardiotoxicity in HER2-positive breast cancer patients.
- Open Access
- 17 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (20) , 6103
Core Lab Adjudication of the ACURATE neo2 Hemodynamic Performance Using Computed-Tomography-Corrected Left Ventricular Outflow Tract Area
(1) Background: Hemodynamic assessment of prosthetic heart valves using conventional 2D transthoracic Echocardiography-Doppler (2D-TTE) has limitations. Of those, left ventricular outflow tract (LVOT) area measurement is one of the major limitations of the continuity equation, which assumes a circular LVOT. (2) Methods: This study comprised 258 patients with severe aortic stenosis (AS), who were treated with the ACURATE neo2. The LVOT area and its dependent Doppler-derived parameters, including effective orifice area (EOA) and stroke volume (SV), in addition to their indexed values, were calculated from post-TAVI 2D-TTE. In addition, the 3D-LVOT area from pre-procedural MDCT scans was obtained and used to calculate corrected Doppler-derived parameters. The incidence rates of prosthesis patient mismatch (PPM) were compared between the 2D-TTE and MDCT-based methods (3) Results: The main results show that the 2D-TTE measured LVOT is significantly smaller than 3D-MDCT (350.4 ± 62.04 mm2 vs. 405.22 ± 81.32 mm2) (95% Credible interval (CrI) of differences: −55.15, −36.09), which resulted in smaller EOA (2.25 ± 0.59 vs. 2.58 ± 0.63 cm2) (Beta = −0.642 (95%CrI of differences: −0.85, −0.43), and lower SV (73.88 ± 21.41 vs. 84.47 ± 22.66 mL), (Beta = −7.29 (95% CrI: −14.45, −0.14)), respectively. PPM incidence appears more frequent with 2D-TTE- than 3D-MDCT-corrected measurements (based on the EOAi) 8.52% vs. 2.32%, respectively. In addition, significant differences regarding the EOA among the three valve sizes (S, M and L) were seen only with the MDCT, but not on 2D-TTE. (4) Conclusions: The corrected continuity equation by combining the 3D-LVOT area from MDCT with the TTE Doppler parameters might provide a more accurate assessment of hemodynamic parameters and PPM diagnosis in patients treated with TAVI. The ACURATE neo2 THV has a large EOA and low incidence of PPM using the 3D-corrected LVOT area than on 2D-TTE. These findings need further confirmation on long-term follow-up and in other studies.
- 17 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (20) , 6103
Open AccessCore Lab Adjudication of the ACURATE neo2 Hemodynamic Performance Using Computed-Tomography-Corrected Left Ventricular Outflow Tract Area
(1) Background: Hemodynamic assessment of prosthetic heart valves using conventional 2D transthoracic Echocardiography-Doppler (2D-TTE) has limitations. Of those, left ventricular outflow tract (LVOT) area measurement is one of the major limitations of the continuity equation, which assumes a circular LVOT. (2) Methods: This study comprised 258 patients with severe aortic stenosis (AS), who were treated with the ACURATE neo2. The LVOT area and its dependent Doppler-derived parameters, including effective orifice area (EOA) and stroke volume (SV), in addition to their indexed values, were calculated from post-TAVI 2D-TTE. In addition, the 3D-LVOT area from pre-procedural MDCT scans was obtained and used to calculate corrected Doppler-derived parameters. The incidence rates of prosthesis patient mismatch (PPM) were compared between the 2D-TTE and MDCT-based methods (3) Results: The main results show that the 2D-TTE measured LVOT is significantly smaller than 3D-MDCT (350.4 ± 62.04 mm2 vs. 405.22 ± 81.32 mm2) (95% Credible interval (CrI) of differences: −55.15, −36.09), which resulted in smaller EOA (2.25 ± 0.59 vs. 2.58 ± 0.63 cm2) (Beta = −0.642 (95%CrI of differences: −0.85, −0.43), and lower SV (73.88 ± 21.41 vs. 84.47 ± 22.66 mL), (Beta = −7.29 (95% CrI: −14.45, −0.14)), respectively. PPM incidence appears more frequent with 2D-TTE- than 3D-MDCT-corrected measurements (based on the EOAi) 8.52% vs. 2.32%, respectively. In addition, significant differences regarding the EOA among the three valve sizes (S, M and L) were seen only with the MDCT, but not on 2D-TTE. (4) Conclusions: The corrected continuity equation by combining the 3D-LVOT area from MDCT with the TTE Doppler parameters might provide a more accurate assessment of hemodynamic parameters and PPM diagnosis in patients treated with TAVI. The ACURATE neo2 THV has a large EOA and low incidence of PPM using the 3D-corrected LVOT area than on 2D-TTE. These findings need further confirmation on long-term follow-up and in other studies.
- 12 May 2022
- Published by SAGE Publications in Human Antibodies
- Vol. 30 (2) , 79-96
HLA alleles and haplotype frequencies in Iranian population
BACKGROUND: HLA genotyping is a prerequisite for selection of suitable donors in the process of bone marrow transplantation. METHODS: In the current study, the frequencies of HLA-A, -B, -C and -DRB1 alleles and A-B-C-DRB1 haplotypes were assessed in 855 healthy Iranian persons using a low-resolution sequence specific primer (SSP) kit. RESULTS: Frequencies were compared between 11 subpopulations including Armani, Balouch, Bandari, Turk, Turkaman, Arab, Fars, Kurd, Gilaki, Lor and Mazani. In total, 17 HLA-A alleles were detected, one of which (HLA-A*74) was present only among Lors. HLA-A*23 and -A*26 were the most frequent HLA-A alleles among Armanis. HLA-A*23 was also common among Turkamans. HLA-A*11 and -A*26 were most frequent among the Balouch subpopulation. The former allele was also frequent among Bandaris. HLA-A*02 was identified as the most common HLA-A allele among Turk, Arab and Fars subpopulations. HLA-A*30 were strongly enriched among Gilakis. A total of 31 HLA-B alleles were detected across the target population. While all alleles were present among Fars subgroup, Armanis and Turkamans had the lowest degree of diversity among the alleles examined. Moreover, HLA-B*35 and B*49 alleles were strongly enriched among Armanis and Turkamans, respectively. A total of 13 HLA-C alleles were identified across the population, all of which were present in the Fars subpopulation. HLA-C*03 and C*04 were the only HLA-C alleles identified among the Bandari subpopulation. HLA-DRB1*08 was not detected in any subpopulation other than Fars. HLA-DRB1*16 was significantly enriched among Bandaris. These data have practical significance in anthropological studies, disease association investigations and bone marrow transplantation.
- 12 May 2022
- Published by SAGE Publications in Human Antibodies
- Vol. 30 (2) , 79-96
HLA alleles and haplotype frequencies in Iranian population
BACKGROUND: HLA genotyping is a prerequisite for selection of suitable donors in the process of bone marrow transplantation. METHODS: In the current study, the frequencies of HLA-A, -B, -C and -DRB1 alleles and A-B-C-DRB1 haplotypes were assessed in 855 healthy Iranian persons using a low-resolution sequence specific primer (SSP) kit. RESULTS: Frequencies were compared between 11 subpopulations including Armani, Balouch, Bandari, Turk, Turkaman, Arab, Fars, Kurd, Gilaki, Lor and Mazani. In total, 17 HLA-A alleles were detected, one of which (HLA-A*74) was present only among Lors. HLA-A*23 and -A*26 were the most frequent HLA-A alleles among Armanis. HLA-A*23 was also common among Turkamans. HLA-A*11 and -A*26 were most frequent among the Balouch subpopulation. The former allele was also frequent among Bandaris. HLA-A*02 was identified as the most common HLA-A allele among Turk, Arab and Fars subpopulations. HLA-A*30 were strongly enriched among Gilakis. A total of 31 HLA-B alleles were detected across the target population. While all alleles were present among Fars subgroup, Armanis and Turkamans had the lowest degree of diversity among the alleles examined. Moreover, HLA-B*35 and B*49 alleles were strongly enriched among Armanis and Turkamans, respectively. A total of 13 HLA-C alleles were identified across the population, all of which were present in the Fars subpopulation. HLA-C*03 and C*04 were the only HLA-C alleles identified among the Bandari subpopulation. HLA-DRB1*08 was not detected in any subpopulation other than Fars. HLA-DRB1*16 was significantly enriched among Bandaris. These data have practical significance in anthropological studies, disease association investigations and bone marrow transplantation.